zurück

Upadacitinib (new indication: non-radiographic axial spondyloarthritis)

 

Subject:

  • Active Sustance: Upadacitinib
  • Name: Rinvoq®
  • Therapeutic area: Axial spondyloarthritis
  • Pharmaceutical company: AbbVie Deutschland GmbH & Co. KG

 

Time table:

  • Start: 01.09.2022
  • Publication of assessment: 01.12.2022
  • End of public hearing: 22.12.2022
  • Final decision by G-BA: middle of February 2023

 

Comparative therapy:

  • A TNF-α inhibitor (etanercept or adalimumab or golimumab or certolizumab pegol)